|Articles|March 27, 2012

Oracle Announces Next Generation of Oracle Health Sciences Clinical Development Analytics

Focused on helping health sciences organizations increase the productivity and effectiveness of their product development programs, Oracle Health Sciences introduced the newest version of Oracle Health Sciences Clinical Development Analytics. Driven by input from industry partners, the comprehensive business intelligence application includes new functionality that expands visibility into clinical programs and studies, improves the quality and timeliness of clinical trial data and helps to simplify and prioritize the rapidly expanding responsibilities of study managers, clinical data managers, and site monitors.

“Clinical trial sponsors and their CRO partners, navigating increasingly complex and lengthy development cycles, are intently focused on improving data quality and clinical program productivity while reducing costs,” said Neil de Crescenzo, senior vice president and general manager, Oracle Health Sciences. “The newest version of Oracle Health Sciences Clinical Development Analytics, which features integrated content, expanded dashboards, and optimized reporting, delivers the insight that study sponsors, managers, and monitors require to achieve these goals and accelerate the delivery of new products to the market.”

The enhanced solution helps to increase resource utilization by delivering advanced dashboards specifically tailored to clinical trial roles. It features expanded drill-down functionality and key performance indicators that identify areas requiring action or attention, such as targeting underperforming sites. The solution enables organizations to merge data from multiple clinical trial sources, providing a unified view across operational systems on a single screen.

New de-duplication technology supports reports that combine both clinical operations and data management information to monitor enrollment progress, optimize productivity at site visits and help to reduce monitoring-related travel expenses. Oracle Health Sciences Clinical Development Analytics also delivers visibility across the entire portfolio of clinical trials, which enables greater insight into subject recruitment and site performance to empower managers and clinical monitors to better target resources to key sites which will help accelerate trial completion.

With more than 100 pre-built reports and over 500 pre-built measurements and attributes for custom reporting, Oracle Health Sciences Clinical Development Analytics can provide immediate business benefit out of the box, while providing an extensible framework for adding additional metrics aligned to targeted business processes. To enable anytime, anywhere access, the solution can be used in conjunction with Oracle Business Intelligence Mobile application for Apple iPhone and iPad to give mobile users access to the latest performance management information.


Related to this article

© photon_photo - © photon_photo - stock.adobe.com
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
What Expanding AI Ecosystems Mean for Sponsor Complexity and Oversight
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.
Where AI Governance in Clinical Development Falls Short
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, identifies three recurring failure modes in AI governance frameworks—and explains why responsible AI must be an ongoing operating discipline, not a one-time approval gate.